CN106344808A - Compound dendrobium officinale health care product capable of assisting in reducing blood sugar - Google Patents
Compound dendrobium officinale health care product capable of assisting in reducing blood sugar Download PDFInfo
- Publication number
- CN106344808A CN106344808A CN201610774382.2A CN201610774382A CN106344808A CN 106344808 A CN106344808 A CN 106344808A CN 201610774382 A CN201610774382 A CN 201610774382A CN 106344808 A CN106344808 A CN 106344808A
- Authority
- CN
- China
- Prior art keywords
- dendrobium officinale
- parts
- compound
- officinale health
- compound dendrobium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 95
- 241001076416 Dendrobium tosaense Species 0.000 title claims abstract description 92
- 230000036541 health Effects 0.000 title claims abstract description 91
- 239000008280 blood Substances 0.000 title abstract description 63
- 210000004369 blood Anatomy 0.000 title abstract description 63
- 235000000346 sugar Nutrition 0.000 title abstract description 31
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 239000009636 Huang Qi Substances 0.000 claims description 30
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 29
- 239000008187 granular material Substances 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 229930013930 alkaloid Natural products 0.000 claims description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 6
- 229930003944 flavone Natural products 0.000 claims description 6
- 235000011949 flavones Nutrition 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 241001523681 Dendrobium Species 0.000 claims description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
- 235000021286 stilbenes Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 44
- 239000008103 glucose Substances 0.000 abstract description 44
- 239000003814 drug Substances 0.000 abstract description 37
- 230000037396 body weight Effects 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 7
- 210000000496 pancreas Anatomy 0.000 abstract description 6
- 241000045403 Astragalus propinquus Species 0.000 abstract description 3
- 235000006533 astragalus Nutrition 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- 230000003907 kidney function Effects 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 88
- 241000699670 Mus sp. Species 0.000 description 48
- 238000012360 testing method Methods 0.000 description 31
- 230000007774 longterm Effects 0.000 description 28
- 235000001727 glucose Nutrition 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000002893 slag Substances 0.000 description 6
- 229940054269 sodium pyruvate Drugs 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000143437 Aciculosporium take Species 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a sugar-reducing health care product, and discloses a compound dendrobium officinale health care product capable of assisting in reducing the blood sugar. The compound dendrobium officinale health care product is prepared from the following raw materials in parts by weight: 12 to 24 parts of fresh dendrobium officinale, 3 to 6 parts of astragalus membranaceus, 3 to 6 parts of radix rehmanniae recen and 2 to 4 parts of folium mori. The raw materials for the compound dendrobium officinale health care product disclosed by the invention are from medicine and food homologous raw materials or raw materials for health care food; the compound dendrobium officinale health care product mainly assists in reducing fasting blood glucose of a diaberic patient and improving the sugar tolerance of the patient; meanwhile, the weight to body weight ratio of pancreas can be obviously increased, the function of pancreatic beta cells can be promoted, liver and kidney function lesions caused by diabetic complications are improved, and the immunity is enhanced; furthermore, the compound dendrobium officinale health care product can be used for early prevention of diabetes; no toxic or side effects are caused after people take the product for a long time.
Description
Technical field
The present invention relates to hypoglycemic health-care product technical field, disclose a kind of compound dendrobium officinale health care of auxiliary hyperglycemic
Product.
Background technology
The normal level of blood glucose is divided into fasting glucose and two hours blood glucose after the meal, is respectively as follows: fasting glucose its normal range
For below 6.1mmol/l, two hours blood glucoses are below 7.8mmol/l after the meal, are just referred to as hyperglycemia if above this scope, just
In the case of often, by hormonal regulation and this two big regulating system of neuroregulation, human body can guarantee that the source of blood glucose and outlet keep
Balance, makes blood glucose maintain certain level.But in inherited genetic factorss (as Diabetes family history) and environmental factorss (as irrational
Diet, obesity etc.) collective effect under, two big regulating systems get muddled, and arise that the rising of blood sugar level.And blood glucose value
Persistently become as hyperglycemia beyond normal level for a long time.
With the increasingly raising of modern life level, the food of high glucose and high fat fat also pours in our dining table, especially
The youngster being present is keen to western fast food, not eating vegetable and fruit and shortage motion, and permanent living habit may
Lead to high blood glucose.And hyperglycemia is particularly likely that the early symptom of diabetes simultaneously, current diabetes patient groups have got over
Carry out more rejuvenation, or even Children Diabetes occur.So effective control blood glucose is to prevent hyperglycemia from developing into the important of diabetes
One of means, for diabeticss, control blood glucose to be also to prevent aggravation and prevent and mitigate the effective of complication
One of approach.
The commonly used diabetes treatment by western medicine of the world of medicine at present, toxic and side effects are big, and are difficult to stop diabetes development, and
And, various medicines have its limitation, as undesirable in Postprandial glucose control, body weight increase, and risk of hypoglycemia increases etc..
In China's traditional medicine, diabetes are called diabetess, first appeared in " Huang di's Canon of Medicine very disease opinion ".Main focus lung,
Stomach, kidney, basic pathogenesis are cloudy body fluid deficiency consumption, scorching inclined Sheng.Quench one's thirst with the passing of time, the state of an illness is out of control, then deficiency of YIN affecting YANG, the bright blood stasis due to loss of body fluid of heat,
And cause impairment of both QI and YIN, deficiency in both YIN and YANG, channels stasis blocking, passages through which vital energy circulates loses supports, and QI and blood is inverse disorderly, internal organs organ is impaired and furuncle, carbuncle, dizzy occurs
The numb pain of dizzy, the thoracic obstruction, deafness, blindness, limbs, lower limb gangrene, renal failure edema, apoplectic coma etc. and disease.Therefore, the treatment of diabetes
Should be based on clearing heat and moistening dryness, YIN nourishing and the production of body fluid promoting.
For example, the Chinese invention patent application of Application No. 201510128319.7 discloses a kind of ferrum of auxiliary hyperglycemic
Skin dendrobium health-care product and preparation method thereof, is combined making using Herba Dendrobii and Radix Panacis Quinquefolii, powder of Radix Puerariae, Radix Trichosanthis, Fructus Schisandrae Chinensis
Become health product, to realize the effect of boosting qi and nourishing yin, clearing away heat and promoting production of body fluid.
Herba Dendrobii, is the dry of orchid Herba Dendrobii (dendrobium officinale kimura et migo)
Dry stem, for traditional rare Chinese medicine.Defend method prison and send out [2002] No. 51 literary composition regulations, Herba Dendrobii is the article that can be used for health food, and
Recorded so that traditional Chinese medicinal materials assortment is single-row in version " Chinese people's republicanism pharmacopeia " (one) in 2010.Herba Dendrobii replenishing YIN and removing heat is moistened
Dry, there is good resisting fatigue, resisting oxygen lack, Herba Dendrobii is exactly the medicine dedicated treating diabetes since ancient times, have bright
Aobvious blood sugar lowering assosting effect.Clinical research shows, Herba Dendrobii not only can strengthen insulin active, can significantly reduce simultaneously
Blood sugar level, makes blood sugar recovery normal.
The Radix Astragali, is leguminous plant Radix Astagali (astragalus membranaceus (fisch.)
Bge.var.mongholic-us (bge.) hsiao) or Radix Astragali (astragalus membranaceus (fisch.)
Bge dry root).There is tonifying Qi and lifting yang, strengthening superficial resistance to stop perspiration, inducing diuresis to remove edema, blood-nourishing of promoting the production of body fluid, the stagnant blood stasis dispelling of row, expelling pus and toxin by strengthening QI, sore is given birth to
The effects such as flesh.Defend method prison and send out [2002] No. 51 literary composition regulations, the Radix Astragali is the article that can be used for health food.Modern pharmacology research table
The bright Radix Astragali has blood sugar reducing function, improves insulin resistant, reduces the accumulation of advanced-glycation end product；Malignant tumor can be promoted thin
The apoptosis of born of the same parents；Improve myocardial hypertrophy, alleviate myocardial ischemia；There is cerebrovascular protective effect and improve the works such as cerebral retrogressive sexually transmitted disease (STD) change
With.
Radix Rehmanniae, is the dried root of scrophulariaceae rehmannia glutinosa plant (rehmannia glutinosa libosch.).Have
Clearing away heat and cooling blood, effect of YIN nourishing and the production of body fluid promoting.Defend method prison and send out [2002] No. 51 literary composition regulations, Radix Rehmanniae is the thing that can be used for health food
Product.It has blood sugar lowering, antitumor, heart tonifying blood pressure lowering, hemostasis and multiple effect such as antiinflammatory and antiallergic.
Folium Mori, are the dried leaves of moraceae plants mulberry (morus alba l.).There is dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, liver heat removing bright
Purpose effect.Defend method prison and send out [2002] No. 51 literary composition regulations, Folium Mori are to be food and the article of medicine.There is blood sugar lowering, fall
Multiple effects such as blood pressure, blood fat reducing, antibacterial anti-inflammatory, defying age, resisting fatigue, beauty treatment removing toxic substances.Modern medicine study shows, in Folium Mori
The n- sugar compounds (n-containing-sugars) containing, have suppression blood glucose rise pharmacological action, can be used for preventing and treating and
Treatment diabetes.
Content of the invention
For solving above-mentioned technical problem, the invention discloses a kind of compound dendrobium officinale health product of auxiliary hyperglycemic, adopt
With the method for secondary purification, prevent in complex health care product the activity decrease of Herba Dendrobii active ingredient and improve active ingredient and extract
Rate.Concrete technical scheme is as follows:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material include fresh Herba Dendrobii, the Radix Astragali, Radix Rehmanniae with
And Folium Mori, four taste raw materials are by weight: 12～24 parts of fresh Herba Dendrobii, 3～6 parts of the Radix Astragali, 3～6 parts of Radix Rehmanniae, Folium Mori 2
～4 parts.Wherein, the Radix Astragali, Radix Rehmanniae and Folium Mori are dry product.
Preferably, in raw material components, fresh Herba Dendrobii with the weight ratio of the Radix Astragali and Radix Rehmanniae and Folium Mori is: 12:3:3:
2.Because conventional Chinese medicine divides cold, hot, warm, flat four classes by the property of medicine, in this health product, Herba Dendrobii sweet in the mouth, cold nature；Radix Astragali taste
Sweet, tepor；Radix Rehmanniae sweet in the mouth, cold in nature；Folium Mori bitter in the mouth, sweet, cold in nature.The medical material of removing heat from blood QI invigorating is a lot, but mostly cold, the present invention
From the mutual proportioning of four kinds of medical materials can balance the property of medicine of blood sugar lowering, it is to avoid the property of medicine is excessively cold.This proportioning is real through for a long time
Test the optimal proportion that research obtains, under this proportion, the cooperation of the four Chinese medicine material property of medicine is optimal, and drug effect is best.
Further, described compound dendrobium officinale health product are using the liquid decocting extraction process concentration.
Further, described compound dendrobium officinale health product are using decocting after extraction process concentration, by being spray-dried one
The granule of one-step forming.In described granule, active constituent content is: polysaccharide >=40.0%, alkaloid >=8.0%, total flavones >=
3.0%.
Further, described compound dendrobium officinale health product are using decocting after extraction process concentration, by being spray-dried shape
Become granule, be crushed to mesh number more than 100 mesh, and then the tablet being pressed into by tablet machine.Described tablet, every sheet weight is 0.4
～0.5g, wherein: polysaccharide >=100mg, alkaloid >=20mg, general flavone content >=7.5mg.
Compared with prior art, beneficial effects of the present invention are as follows: used by the compound dendrobium officinale health promoting product of the present invention
Raw material comes from integration of edible and medicinal herbs or the raw material that can be used for health food, is mainly used in auxiliary and reduces diabeticss fasting glucose,
Improve glucose tolerance of patient, pancreas weight and weight ratio can be dramatically increased simultaneously, promote islet beta cell function, improve because of diabetes
The Liver and kidney function that complication leads to damages, enhance immunity, and can be used for the early prevention of diabetes, the nontoxic pair of long-term taking
Effect, the present invention can with nourishing YIN and clearing away heat, QI invigorating consolidates, removing heat from blood promotes the production of body fluid, inducing diuresis to remove edema, meanwhile, though Radix Rehmanniae can YIN nourishing and the production of body fluid promoting,
" diarrhea due to hypofunction of the spleen " person's inedibility, it is insufficiency of the spleen weak that the Radix Astragali then can alleviate kidney, complements each other with Radix Rehmanniae, in addition, Folium Mori removing heat from blood is anti-ageing
Always, therefore, finished product of the present invention also has the kidney invigorating, removing heat from blood, the effect of pathogenic fire reducing, have existing fall blood especially for diabetic nephropathy
The curative effect that sugared health product do not have.
Brief description
Fig. 1 is the impact figure to diabetes db/db mice random blood sugar for the compound dendrobium officinale health product long term administration；
Fig. 2 is the impact figure to diabetes db/db mice fasting glucose for the compound dendrobium officinale health product long term administration；
Fig. 3 is the impact figure to diabetes db/db mice food ration for the compound dendrobium officinale health product long term administration；
Fig. 4 is the impact to the Mouse oral glucose tolerance of diabetes db/db for the compound dendrobium officinale health product long term administration
Figure；
Fig. 5 is the impact to diabetes db/db mice plasma insulin content for the compound dendrobium officinale health product long term administration
Figure；
Fig. 6 is the impact to diabetes db/db injected in mice acetone acid tolerance for the compound dendrobium officinale health product long term administration
Figure；
Fig. 7 is compound dendrobium officinale health product long term administration under diabetes db/db injected in mice acetone acid tolerance curve
The impact figure of area.
Specific embodiment
Purpose, technical scheme and advantage for making the embodiment of the present invention are clearer, test number below in conjunction with the present invention
According to being clearly and completely described to the technical scheme of the embodiment of the present invention.Obviously, described embodiment is the present invention
A part of embodiment, rather than whole embodiments.Based on described embodiments of the invention, those of ordinary skill in the art
The every other embodiment being obtained on the premise of without creative work, broadly falls into the scope of protection of the invention.
Embodiment 1:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 3 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 2 parts of Folium Mori.
This product is using the liquid decocting extraction process concentration, and then can make granule or buccal tablet.Concrete employing
Decocting extraction process is:
(1) by weight proportion, weigh corresponding raw material respectively；
(2) the decoction extracting of Herba Dendrobii: take fresh Herba Dendrobii, using water extraction, obtain an extracting solution and iron sheet
Herba Dendrobii slag；
Method particularly includes:
A. take fresh Herba Dendrobii, once purged, it is cut into segment, add the pure water of 10 times of fresh Herba Dendrobii quality,
Smash and squeeze the juice, the Herba Dendrobii obtaining slag inclusion fresh is squeezed the juice；
B. fresh for the Herba Dendrobii of slag inclusion squeezing the juice is poured into decoction in rustless steel decoction pot, keep fresh 30 points of micro-boiling of squeezing the juice in pot
Clock；The micro-boiling time can control according to actual needs between 25 minutes to 35 minutes；
C. squeeze the juice fresh to the slag inclusion decocting is centrifuged, and obtains an extracting solution and Herba Dendrobii slag.
(3) the decoction extracting of mixture: Herba Dendrobii slag is mixed with the Radix Astragali, Radix Rehmanniae, Folium Mori, using water extraction, obtains
Obtain secondary raffinate；
(4) the secondary raffinate mixing that the extracting solution obtaining step (two) and step (three) obtain, obtains compound recipe
Dendrobium officinale health product liquor.
Compound dendrobium officinale health product liquor is passed through to be spray-dried with the granule of one-step shaping.Make graininess compound recipe iron sheet
Dendrobium health-care product.In granule, active constituent content is: polysaccharide >=40.0%, alkaloid >=8.0%, total flavones >=3.0%.This reality
Apply the compound dendrobium officinale health-care product particle in example, every bag contains 3.0 grams of granule.
Specifically comprises the processes of: spray drying treatment is carried out to compound dendrobium officinale health product liquor, obtains granular compound recipe
Dendrobium officinale health product.Granule health product can be drunk as electuary, instant edible and absorption it is also possible to make capsule, to cover
The bad smell of lid medicine, rapid-action, good absorbing.
Compound dendrobium officinale health-care product particle is crushed to mesh number more than 100 mesh, and then the piece being pressed into by tablet machine
Agent.Described tablet, every sheet weight be 0.4～0.5g, the tablet weight made in the present embodiment be 0.45g wherein: polysaccharide >=
100mg, alkaloid >=20mg, general flavone content >=7.5mg.
Specifically comprises the processes of: granular compound dendrobium officinale health product are pulverized, until granularity is more than 100 mesh, leads to
Cross the compound dendrobium officinale health product that tablet machine is compressed into tablet form.The mouthfeel of tablet can also be improved by adding other compositions,
Make buccal tablet.
Embodiment 2:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 3 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 3:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 3 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 4:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 6 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 5:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 6 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 6:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 6 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 7:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 6 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 8:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 12
Part, 3 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 9:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 3 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 10:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 3 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 11:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 3 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 12:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 6 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 13:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 6 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 2 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 14:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 6 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 4 parts of Folium Mori.(this kind of weight ratio is actually same as Example 1)
Preparation method is with embodiment 1.
Embodiment 15:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 6 parts of the Radix Astragali, 3 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Embodiment 16:
A kind of compound dendrobium officinale health product of auxiliary hyperglycemic, raw material components are: by weight, fresh Herba Dendrobii 24
Part, 3 parts of the Radix Astragali, 6 parts of Radix Rehmanniae, 4 parts of Folium Mori.
Preparation method is with embodiment 1.
Wherein, the medicinal effects of embodiment 1 are optimal.The experimental data that for embodiment 1 carry out is presented herein below illustrate:
Experimental data:
Shanghai Pharmaceutical Inst., Chinese Academy of Sciences tests, to the granular compound dendrobium officinale health product in embodiment one
The experimental study for the treatment of diabetes db/db mice.
1. laboratory animal
Bks.cg-dock7m+ /+leprdb/j mice (db/db mice) 40, male and female half and half, by Chinese Academy of Sciences Shanghai
Institute of materia medica's autonomous replication from after U.S.'s jackson laboratory introduction, the age starting when testing is 10-11 week, starts to try
Body weight when testing is 40～50g.
2. the preparation of medicine
The compound dendrobium officinale health-care product particle being prepared into using the process of embodiment one.
3. experimental design
3.1 dosage settings
It is little to spontaneous patients with type Ⅰ DM db/db that this experiment is intended to discussion compound dendrobium officinale health-care product particle chronic administration
The impact of Mus.The clinical administration dosage of compound dendrobium officinale health-care product particle is 1-1.5g, compound dendrobium officinale health product accordingly
Dosage setting on db/db mice for the granule is 400mg/kg, by daily single.
3.2 dosage settings and group
3.2.1 model control group: 0.5%cmc-na (sodium carboxymethyl cellulose).
3.2.2 test medicine group: compound dendrobium officinale health-care product particle 400mg/kg.
4. experimentation
4.1 packet
40 db/db mices (male 20, female 20), enter this institute Animal House, raise to 10-11 during 4-5 week old
Start during week old to test.All db/db mices measure random blood sugar and random body weight in first 2 day morning 9:00 of administration, prohibit afterwards
Food 6h (can't help water) measures fasting glucose, empty body weight mensure insulin content of taking a blood sample.Choose 16 db/db mices, its with
Machine blood glucose is more than 11.1mmol/l.According to mice random blood sugar, random body weight, fasting glucose and empty body weight, mice is divided into 2
Group, every group 8,4 male 4 is female.It is respectively model control group and test medicine group.Concrete packet situation is shown in Table 1.
Table 1. laboratory animal is grouped situation
Note: < 0.01 compared with model control group for #, p.
4.2 administration
Oral administration gavage is administered, and administration volume is 10ml/kg, is given daily 1 time.Administration time is daily 9:00-10:00.
4.3 observation index
4.3.1 random blood sugar
Model control group, test medicine group mice after first administration (9:00-11:00) on the 7th, 14,21,28,35,41st
Measure each group mice random blood sugar.
4.3.2 fasting glucose
Model control group, test medicine group mice measure random blood sugar in the 7th, 14,21,28,35,41 days after first administration
Afterwards, remove food hungry 6 hours, measure each group mice fasting glucose, as follows calculating blood glucose rate of descent:
Blood glucose rate of descent=(matched group blood glucose-administration group blood glucose)/matched group blood glucose x100%.
4.3.3 random body weight and empty body weight
Each group mice measures random body weight and empty body weight before measuring random blood sugar and fasting glucose.
4.3.4 food ration
The daily food ration measuring each group mice.
4.3.5 oral glucose tolerance test
Model control group, test medicine group mice carry out oral glucose tolerance test after being administered 4 weeks.Mice fasting 6h
Gavage glucose 1.5g/kg afterwards, measures to before sugar, to blood glucose value when 15,30,60,90 and 120min after sugar, calculates 120min
Interior Area under the curve of blood glucose (auc).
Auc (mmol/l.min)=(bg0+bg15)×15/2+(bg15+bg30)×15/2+(bg30+bg60)×30/2+
(bg60+bg90)×30/2+(bg90+bg120)×30/2
Note: bg0、bg15、bg30、bg60、bg90And bg120Represent respectively to before sugar, to sugar after 15,30,60,90 and 120min
When blood glucose value.
4.3.6 acetone acid tolerance test
Model control group, test medicine group mice carry out acetone acid tolerance test after being administered 6 weeks.Abdomen after mice fasting 6h
Sodium Pyruvate 1.5g/kg is injected in chamber, measures to before Sodium Pyruvate, to blood when 15,30,60,90 and 120min after Sodium Pyruvate
Sugar value, calculates the Area under the curve of blood glucose (auc) in 120min.
Auc (mmol/l.min)=(bg0+bg15)×15/2+(bg15+bg30)×15/2+(bg30+bg60)×30/2+
(bg60+bg90)×30/2+(bg90+bg120)×30/2
Note: bg0、bg15、bg30、bg60、bg90And bg120Represent respectively to before Sodium Pyruvate, to 15 after Sodium Pyruvate, 30,
60th, 90 and 120min when blood glucose value.
4.3.7 dissecting
After each group animal is administered 5 weeks, hungry 6h takes fasting blood, is placed in -80 DEG C of refrigerators and preserves.
Each group animal, after being administered 6 weeks, terminates test, and cervical dislocation puts to death animal, separates liver, kidney, pancreas, leg
Muscle, subcutaneous fat, epididymal adipose tissues and perirenal fat etc. are organized, and weigh, and calculate its ratio with body weight.
4.3.8 the mensure of plasma insulin
Using enzyme-linked immunoassay method plasma insulin content.
5. data processing and statistical analysiss
Data is with means standard deviationRepresent, statistical analysis are carried out using student-ttest to data, p <
0.05 as has significant difference.When test medicine group is compared with model control group, blood glucose rate of descent >=20%, and have aobvious
Writing sex differernce is p < 0.05 then it is assumed that medicine has definite hypoglycemic activity.
All data are all represented with form, partial data simultaneously to scheme to represent, but because this test group is more, for ensureing
Standard deviation is omitted by the clarity of figure in mapping.
5. data record and data store
The record of 5.1 all data, including test data sheet, computer printout data, self-reacting device recording materials etc., will
Accomplish timely, direct, accurate, clear and be difficult to eliminate.
When the data of 5.2 records need modification, will keep former and record clearly discernable, the content of revision will write on former record
Side, and indicate the reasons why change and modification date, reviser signs.
5.3 data storages
All experiment associated materials, all will be saved in Chinese section including initial data, experimental program etc. after the completion of experiment
Shanghai medicine institute of institute.
6. result of the test
The impact to diabetes db/db mice random blood sugar for the 6.1 compound dendrobium officinale health product long term administrations
From table 2 and Fig. 1, test medicine group substantially reduces db/db mice random blood sugar on the 1st week upon administration；Administration
Random blood sugar decrease to some degree in 2nd, 3,4 weeks afterwards, but no obvious significant difference；To after be administered 5 and 6 weeks, at random
Blood glucose declines substantially；After being administered 6 weeks, the mean random blood glucose rate of descent of test medicine group is 20.35%, the results are shown in Table 3.
Note: < 0.05 compared with model control group for *, p；#, p < 0.01, compared with model control group.
The impact to diabetes db/db mice random blood sugar (mmol/l) for the table 2. compound dendrobium officinale health product long term administration
Table 3. compound dendrobium officinale health product long term administration diabetes db/db mice random blood sugar rate of descent (%)
The impact to diabetes db/db mice fasting glucose for the 6.2 compound dendrobium officinale health product long term administrations
Compound dendrobium officinale health product one time a day administration chronic treatment 6 weeks, a certain degree of can reduce diabetes db/db
The fasting glucose of mice.Compound dendrobium officinale health product 400mg/kg only upon administration 1 and 4 weekSubstantially reduce db/
Db mice fasting glucose, has obvious significant difference with model control group；After administration, 2,3,5 and 6 weeks fasting glucose have one
Determine the reduction (14.2%, 24.4% and 19.8%) of degree, but no obvious significant difference compared with model group.Successive administration
After 6 weeks, the average blood sugar rate of descent of compound dendrobium officinale health product 400mg/kg group is 22.52%, the results are shown in Table 5.
Note: < 0.05 compared with model control group for *, p；#, p < 0.01, compared with model control group.
The impact to diabetes db/db mice fasting glucose (mmol/l) for the table 4 compound dendrobium officinale health product long term administration
Diabetes db/db mice fasting glucose rate of descent (%) after table 5 compound dendrobium officinale health product long term administration
The shadow of 6.3 compound dendrobium officinale health product long term administration random body weight and empty body weight to diabetes db/db mice
Ring
During test, the random body weight of each group mice and empty body weight sustainable growth.Compound dendrobium officinale health product are once a day
Administration, after 3 weeks, the random body weight of test medicine group has obvious reduction, effect with empty body weight compared with model control group to chronic treatment
Fruit is until experiment terminates (table 6-7).
The impact to the random body weight (g) of diabetes db/db mice for the table 6. compound dendrobium officinale health product long term administration
The impact to diabetes db/db mice empty body weight (g) for the table 7 compound dendrobium officinale health product long term administration
The impact to diabetes db/db mice food ration for the 6.4 compound dendrobium officinale health product long term administrations
After compound dendrobium officinale health product are administered 6 weeks once a day, test medicine group removes several first days food rations slightly
Outside less than model control group, whole test during food ration no marked difference compared with model control group, result is shown in Fig. 3.
The impact to diabetes db/db Mouse oral carbohydrate tolerance for the 6.5 compound dendrobium officinale health product long term administrations
After compound dendrobium officinale health product are administered 4 weeks once a day, test medicine group is administered orally to diabetes db/db mice
Glucose tolerance has no significant effect, and the results are shown in Table 8 and Fig. 4.
The impact to diabetes db/db Mouse oral carbohydrate tolerance for the table 8. compound dendrobium officinale health product long term administration
The impact to diabetes db/db mice plasma insulin content for the 6.6 compound dendrobium officinale health product long term administrations
After compound dendrobium officinale health product are administered 6 weeks once a day, can a certain degree of increase plasma insulin content,
But no obvious significant difference, the results are shown in Table 9, Fig. 5 compared with model control group.
The impact to diabetes db/db mice plasma insulin content for the table 9. compound dendrobium officinale health product long term administration
Note: < 0.05 compared with model control group for *, p；< 0.01 compared with model control group for #, p；
The impact to diabetes db/db mice acetone acid tolerance for the 6.7 compound dendrobium officinale health product long term administrations
After compound dendrobium officinale health product are administered 6 weeks once a day, it is little that test medicine group can significantly reduce diabetes db/db
Blood glucose curve in the blood sugar level of 15min, 30min, 60min and 90min after the injection Sodium Pyruvate load of Mus and 120min
Lower area, the results are shown in Table 10 and Fig. 6,7.
Note: *, p < 0.05, compared with model control group；#, p < 0.01, compared with model control group.
The impact to diabetes db/db injected in mice acetone acid tolerance for the table 10. compound dendrobium officinale health product long term administration
The impact to each adipose tissue mass of diabetes db/db mice for the 6.8 compound dendrobium officinale health product long term administrations
As shown in Table 11, after compound dendrobium officinale health product are administered 6 weeks once a day, test medicine group is to db/db mice
Subcutaneous fat, stomach fat, perirenal fat and its have no significant effect with weight ratio.
Table 11 compound dendrobium officinale health product long term administration is to diabetes db/db mouse adipose tissue and fatty weight ratio
Impact
The impact to diabetes db/db mouse liver, kidney and pancreas for the 6.9 compound dendrobium officinale health product long term administrations
As shown in Table 12, after compound dendrobium officinale health product are administered 6 weeks once a day, test medicine group is to db/db mice
Liver weight and its have no significant effect with weight ratio；Test medicine group can significance reduce db/db mouse kidney weight and its with
Weight ratio；Examination thing test medicine group has no significant effect to db/db mice pancreatic weight, but can dramatically increase pancreas weight and body
Anharmonic ratio.Diabetic nephropathy can lead to the high filtration of glomerule and renal hypertrophy, and the results show compound dendrobium officinale health product are long
Phase administration has certain curative effect to diabetic nephropathy.
The impact to diabetes db/db mouse liver, kidney and pancreas for the table 12 compound dendrobium officinale health product long term administration
The foregoing is only presently preferred embodiments of the present invention and experimental data, not in order to limit the present invention.All
Any modification, equivalent and improvement of being made within the spirit and principles in the present invention etc., should be included in the guarantor of the present invention
Within the scope of shield.
Claims (8)
1. a kind of compound dendrobium officinale health product of auxiliary hyperglycemic are it is characterised in that raw material includes fresh Herba Dendrobii, Huang
Stilbene, Radix Rehmanniae and Folium Mori, four taste raw materials are by weight: 12～24 parts of fresh Herba Dendrobii, 3～6 parts of the Radix Astragali, Radix Rehmanniae 3
～6 parts, 2～4 parts of Folium Mori.
2. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 1 are it is characterised in that the Radix Astragali, the Radix Rehmanniae
Yellow and Folium Mori are dry product.
3. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 2 are it is characterised in that raw material components
In, fresh Herba Dendrobii with the weight ratio of the Radix Astragali and Radix Rehmanniae and Folium Mori is: 12:3:3:2.
4. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 3 are it is characterised in that described compound recipe ferrum
Skin dendrobium health-care product is using the liquid decocting extraction process concentration.
5. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 3 are it is characterised in that described compound recipe ferrum
Skin dendrobium health-care product is using decocting after extraction process concentration, by being spray-dried the granule of one-step shaping.
6. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 5 are it is characterised in that in described granule
Active constituent content is: polysaccharide >=40.0%, alkaloid >=8.0%, total flavones >=3.0%.
7. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 3 are it is characterised in that described compound recipe ferrum
Skin dendrobium health-care product be using decoct extraction process concentrate after, by be spray-dried formed granule, be crushed to mesh number more than 100 mesh,
And then the tablet being pressed into by tablet machine.
8. the compound dendrobium officinale health product of auxiliary hyperglycemic according to claim 7 are it is characterised in that described tablet,
Every sheet weight is 0.4～0.5g, wherein: polysaccharide >=100mg, alkaloid >=20mg, general flavone content >=7.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610774382.2A CN106344808A (en) | 2016-08-31 | 2016-08-31 | Compound dendrobium officinale health care product capable of assisting in reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610774382.2A CN106344808A (en) | 2016-08-31 | 2016-08-31 | Compound dendrobium officinale health care product capable of assisting in reducing blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106344808A true CN106344808A (en) | 2017-01-25 |
Family
ID=57857527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610774382.2A Pending CN106344808A (en) | 2016-08-31 | 2016-08-31 | Compound dendrobium officinale health care product capable of assisting in reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344808A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112457423A (en) * | 2020-12-01 | 2021-03-09 | 温州大学 | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524237A (en) * | 2015-01-14 | 2015-04-22 | 赤水市信天中药产业开发有限公司 | Dendrobium nobile soft capsule and preparing method thereof |
| CN104784505A (en) * | 2015-03-23 | 2015-07-22 | 广西龙凤山生物科技有限责任公司 | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof |
| CN105412615A (en) * | 2015-12-22 | 2016-03-23 | 王琪 | Traditional Chinese medicine composition for treating diabetes caused by deficiency of qi and yin |
| CN105535460A (en) * | 2016-01-07 | 2016-05-04 | 天津市康瑞药业有限公司 | Traditional Chinese medicine dropping pills for treating mild type 2 diabetes and preparation method thereof |
-
2016
- 2016-08-31 CN CN201610774382.2A patent/CN106344808A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524237A (en) * | 2015-01-14 | 2015-04-22 | 赤水市信天中药产业开发有限公司 | Dendrobium nobile soft capsule and preparing method thereof |
| CN104784505A (en) * | 2015-03-23 | 2015-07-22 | 广西龙凤山生物科技有限责任公司 | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof |
| CN105412615A (en) * | 2015-12-22 | 2016-03-23 | 王琪 | Traditional Chinese medicine composition for treating diabetes caused by deficiency of qi and yin |
| CN105535460A (en) * | 2016-01-07 | 2016-05-04 | 天津市康瑞药业有限公司 | Traditional Chinese medicine dropping pills for treating mild type 2 diabetes and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘国艳等: "桑叶提取物对糖尿病小鼠降血糖效果的研究", 《扬州大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112457423A (en) * | 2020-12-01 | 2021-03-09 | 温州大学 | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof |
| CN112457423B (en) * | 2020-12-01 | 2022-04-01 | 温州大学 | Natural extracted compound polysaccharide with function of improving insulin resistance and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN101708295A (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN102343023B (en) | Medicinal composition and preparation method and application thereof | |
| CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN104162094A (en) | Traditional Chinese medicine composition for treating obese polycystic ovary syndrome, and medicinal preparation thereof | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN104138526B (en) | A kind of root of three-nerved spicebush iron sheet ginseng granules agent | |
| CN103223111A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN103191298B (en) | Traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease and preparation method thereof | |
| CN103768407A (en) | Compound blood glucose reducing capsules and preparation method thereof | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN101406598B (en) | Chinese medicine composite for treating diabetes and preparation method thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN101095798B (en) | Chinese traditional medicine for treating canities | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105582274A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN104800771A (en) | Traditional Chinese medicine preparation for treating children sleep terror disorder and preparation method thereof | |
| CN106344808A (en) | Compound dendrobium officinale health care product capable of assisting in reducing blood sugar | |
| CN103751558B (en) | A kind of compound antihypelipidemic pill and preparation method thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN106376928A (en) | Method for preparing compound dendrobium officinale health product assisting in reducing blood sugar | |
| CN105641672A (en) | Composition for treating obesity caused by energy metabolism imbalance and preparation | |
| CN101116683A (en) | Medicine for treating arthritis | |
| CN103861041A (en) | Traditional Chinese medicinal composition for treating acute and chronic rhinitis and preparation method thereof | |
| CN103989762A (en) | Traditional Chinese medicine composition for clearing heat and purging internal organs, and relieving cough and reducing sputum and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1233182 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170125 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1233182 Country of ref document: HK |